Diligence memo · auto-generated · as of July 2, 2026
EnEvolv, Inc.
EnEvolv, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
EnEvolv, Inc. operates in Biotechnology, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
EnEvolv, Inc. has raised $1.8M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.8M on 2014-02-12.
Most recent recorded round closed around 2014-02-12.
Valuation (modeled)modeled
Provath models EnEvolv, Inc. at approximately $80M (range $1.3M–$625M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.19× the median modeled value of Seed Biotechnology companies in 2013–2015 (122 peers) — value vs value, same stage and era. Within the normal band (119% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 12.4 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 26% of Biotechnology peers (4293 compared).
Modeled value ranks above 54% of those peers.
Closest niche peers: Harpoon Medical, Inc., Admittance Technologies, Inc., Bell Biosystems, Inc., Nexstim Plc, Iontera, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.